Haleon PLC

Haleon Plc provides personal healthcare products. The firm focus on consumer healthcare and driven by its purpose of delivering better everyday health with humanity. Its brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. The company is headquartered in Brentford, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.

Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

GlaxoSmithKline

Sanofi

European-listed shares of drugmakers Haleon HLN, -11.81% , GSK GSK, -8.48% and Sanofi SAN, -8.81% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22.

GSK, Sanofi and Haleon slump on worries over Zantac litigation

Haleon PLC ( HLN , Financial) is the world's largest consumer health care company, which was recently spun off of GSK PLC ( GSK , Financial). The company's name was formed from merging the words "hale," which means in good health, and "leon," which is associated with the word Spanish word for lion.

Haleon: The 'Good Health Lion' Now Stalks the Drug Store Aisle

Panadol maker Haleon PLC (LSE:HLN, NYSE:HLN) delivered a ‘solid first building block' with an upbeat trading statement a little over a week after its £30bn spin-out from GSK PLC (LSE:GSK, NYSE:GSK). That at least was the conclusion of US bank Jefferies, which specialises in analysing health and drug stocks.

Is Haleon a buy? This leading US broker delivers its verdict

GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business Haleon ( HLN , Financial) on July 18. Shareholders received one Haleon share for each GSK share owned.

Could GSK's Haleon Spinoff Backfire?

GSK or Haleon: Which Is the Real Beneficiary of This Spinoff?

Unilever

Reckitt Benckiser Group PLC

Consumer goods companies enjoyed a strong week, but what makes them so special? Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB), Unilever PLC (LSE:ULVR) and Haleon PLC (LSE:HLN, NYSE:HLN) are the consumer goods FTSE 100 companies which all posted an impressive set of results and raised guidance for the year.

Unilever, Reckit and Haleon stand strong in tough times, but can it last?

Haleon PLC (LSE:HLN, NYSE:HLN), the spin-out from GSK PLC (LSE:GSK, NYSE:GSK) in which American giant Pfizer also has a significant stake, on Wednesday emulated its erstwhile parent by raising its revenue guidance. The consumer healthcare group, which listed in London and New York last week with a value of around £30bn, said it expects the top line to grow by between 6% and 8% this year, an increase to the range of two percentage points.

Haleon raises revenue guidance after bumper first half

Haleon PLC (LSE:HLN, NYSE:HLN) offers "the best of both worlds", said Citigroup, as it started coverage of the London consumer healthcare newcomer. After it was spun out of GSK PLC (LSE:GSK, NYSE:GSK) on Monday and floated its ADRs in New York yesterday, the investment bank slapped a 'buy' rating on the Weybridge, Surrey-based group's shares, with a 360p price target.

Haleon offers 'the best of both worlds', says Citi

News for Haleon PLC Stock (HLN)